These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 3631560)

  • 1. Erythrocyte fragility screening is not a tool for diagnosis of human malignant hyperthermia.
    Kistler P; Fletcher JE; Rosenberg H
    Anesth Analg; 1987 Oct; 66(10):1004-7. PubMed ID: 3631560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Porcine malignant hyperthermia susceptibility: erythrocytic osmotic fragility.
    O'Brien PJ; Rooney MT; Reik TR; Thatte HS; Rempel WE; Addis PB; Louis CF
    Am J Vet Res; 1985 Jul; 46(7):1451-6. PubMed ID: 4026025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of anaesthetic agents on erythrocyte fragility: comparison of normal and malignant hyperthermia susceptible patients.
    Tolpin EI; Fletcher JE; Rosenberg H; Michaux K
    Can J Anaesth; 1987 Jul; 34(4):366-72. PubMed ID: 3608052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythrocyte osmotic fragility in porcine malignant hyperthermia and effects of halothane.
    Reiner G; Dzapo V
    Zentralbl Veterinarmed A; 1989 Apr; 36(4):269-75. PubMed ID: 2506706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Masseter muscle rigidity and malignant hyperthermia susceptibility.
    Rosenberg H; Fletcher JE
    Anesth Analg; 1986 Feb; 65(2):161-4. PubMed ID: 3942303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Failure of the platelet-halothane nucleotide depletion test as a diagnostic or screening test for malignant hyperthermia.
    Britt BA; Scott EA
    Anesth Analg; 1986 Feb; 65(2):171-5. PubMed ID: 3942305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An in-vivo metabolic test for detecting malignant hyperthermia susceptibility in humans: a pilot study.
    Schuster F; Metterlein T; Negele S; Kranke P; Muellenbach RM; Schwemmer U; Roewer N; Anetseder M
    Anesth Analg; 2008 Sep; 107(3):909-14. PubMed ID: 18713904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of pH, temperature, halothane and its metabolites on osmotic fragility of erythrocytes of malignant hyperthermia-susceptible and resistant pigs.
    Heffron JJ; Mitchell G
    Br J Anaesth; 1981 May; 53(5):499-504. PubMed ID: 7236474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malignant hyperthermia: characterization of erythrocyte membranes from individuals at risk.
    Godin DV; Herring FG; MacLeod PJ
    J Med; 1981; 12(1):35-49. PubMed ID: 6455481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for malignant hyperthermia susceptibility.
    Anderson IL; Rawstron RE; Dunlop DJ
    N Z Med J; 1980 Jun; 91(661):417-9. PubMed ID: 6930029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of chlorocresol vs caffeine on muscle contracture in malignant hyperthermia susceptible patients].
    Ben-Abraham R; Krivosic-Horber RM; Haudcoeur G; Perel A; Adnet PJ
    Harefuah; 1997 Jun; 132(12):839-41, 911. PubMed ID: 9264187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canine stress syndrome/malignant hyperthermia susceptibility: calcium-homeostasis defect in muscle and lymphocytes.
    O'Brien PJ; Pook HA; Klip A; Britt BA; Kalow BI; McLaughlin RN; Scott E; Elliott ME
    Res Vet Sci; 1990 Jan; 48(1):124-8. PubMed ID: 2300706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphorylase ratio and susceptibility to malignant hyperthermia.
    Traynor CA; Van Dyke RA; Gronert GA
    Anesth Analg; 1983 Mar; 62(3):324-6. PubMed ID: 6299136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diagnosis of disposition for malignant hyperthermia--an updated review based on 1,001 studies].
    Olthoff D; Deutrich C; Meinecke CD
    Anaesthesiol Reanim; 1997; 22(2):32-40. PubMed ID: 9235003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for a spontaneous C1840-T mutation in the RYR1 gene after DNA fingerprinting in a malignant hyperthermia susceptible family.
    Steinfath M; Seranski P; Singh S; Fiege M; Wappler F; Schulte Am Esch J; Scholz J
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Oct; 366(4):372-5. PubMed ID: 12237752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [In-vitro-effects of cocaine in skeletal muscle specimens of patients susceptible to malignant hyperthermia].
    Weisshorn R; Wappler F; Fiege M; Gerbershagen M; Schulte Am Esch J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2002 Mar; 37(3):138-43. PubMed ID: 11889614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canine malignant hyperthermia susceptibility: erythrocytic defects--osmotic fragility, glucose-6-phosphate dehydrogenase deficiency and abnormal Ca2+ homeostasis.
    O'Brien PJ; Forsyth GW; Olexson DW; Thatte HS; Addis PB
    Can J Comp Med; 1984 Oct; 48(4):381-9. PubMed ID: 6150753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythrocyte osmotic fragility, serum creatine kinase and its isoenzymes related to body weight in porcine malignant hyperthermia.
    Doizé F; Roux I; DeRoth L
    J Comp Pathol; 1990 May; 102(4):467-73. PubMed ID: 2365858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of lactic acid on water content and osmotic fragility of erythrocytes in vitro.
    Kogawa H; Satoh M; Higuchi T; Fujii-Kiyosue A; Sahara T; Kageyama K
    Cell Mol Biol (Noisy-le-grand); 1995 Sep; 41(6):809-12. PubMed ID: 8535174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative analysis of in vitro contracture tests with ryanodine and a combination of ryanodine with either halothane or caffeine: a comparative investigation in malignant hyperthermia.
    Bendahan D; Guis S; Monnier N; Kozak-Ribbens G; Lunardi J; Ghattas B; Mattei JP; Cozzone PJ
    Acta Anaesthesiol Scand; 2004 Sep; 48(8):1019-27. PubMed ID: 15315621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.